The evidence seems to show that semaglutide/weight loss drugs are causing serious injuries to unwitting patients
Increased thirst is not listed amongst the common adverse effects in the Summary of Product Characteristics (SmPC) approved by the MHRA, though some patients do report experiencing thirst during treatment
[DOI] [PubMed] [Google Scholar] Miners JO, Lillywhite KJ, Yoovathaworn K, Pongmarutai M, Birkett DJ
Key behavioral fraud signals in peptide ecommerce: Copy/paste behavior across fields Multiple checkout attempts from different devices Identical browser fingerprints tied to different emails These patterns dont confirm fraud, but theyre strong warning signs
Individual results with any GLP-1 medication vary significantly
No validated PHQ-2 or PHQ-9 , no dedicated eating-disorder screen, no blood pressure or resting heart rate , no diet history beyond the single 3-option lifestyle self-rating, no exercise history , no broader comorbidity multi-select for hypertension, sleep apnea, NAFLD, PCOS, or GERD, no AUDIT-C -style alcohol quantity-frequency questions, no recreational drug naming (cocaine, opioids, kratom, methamphetamine, cannabis are not asked separately), no pregnancy or breastfeeding screen, no cardiac sudden-death family history , no MEN-2 named separately , no ID upload , and no phone OTP
